Linda preferred her camels behind a stout fence
Odd though
it may seem, sometimes useful information about OVCA appears in the financial
news, For instance right now there is a
flurry of interest in a drug called Rubraca (rubracarib), a PARPi (inhibits
division of cancer cells), Seems a
company named Clovis Oncology, in an effort to avoid being swallowed whole by Big
Pharma, has released results of a recent trial, which shows that Rubraca, their baby, increases PFS (progression-free survival) by an average of 11
months, and has a hazard ratio of 0.65, meaning, I think, that one is 35% less
likely to die than similar folks on a placebo.
Anyway: No great breakthrough,
but welcome nonetheless.
https://finance.yahoo.com/news/clovis-oncologys-rubraca-significantly-improves-132257226.html
Not surprisingly,
Clovis Oncology stock (CLVS) gained almost 25% today. I may buy a few shares anyway; it’s selling
for $2.02/share at the moment. But, for God’s
sake, don’t go all in, whole hog, with your hard earned nest egg! I know about as much about stocks as I do
about brain surgery.
No comments:
Post a Comment